US 11,926,841 B2
AAV-based conditional expression system
Ulrich Koszinowski, Diessen am Ammersee (DE); Simona Langer, Munich (DE); Zsolt Ruzsics, Diessen am Ammersee (DE); and Christian Thirion, Munich (DE)
Filed by SIRION BIOTECH GmbH, Planegg (DE)
Filed on Sep. 22, 2021, as Appl. No. 17/481,576.
Application 17/481,576 is a continuation of application No. 16/073,488, granted, now 11,155,831, previously published as PCT/EP2017/051944, filed on Jan. 30, 2017.
Claims priority of application No. 16153329 (EP), filed on Jan. 29, 2016.
Prior Publication US 2022/0073947 A1, Mar. 10, 2022
Int. Cl. C07H 21/04 (2006.01); C12N 15/86 (2006.01); C12Q 1/02 (2006.01); C12Q 1/6897 (2018.01); C12Q 1/70 (2006.01)
CPC C12N 15/86 (2013.01) [C12Q 1/025 (2013.01); C12Q 1/6897 (2013.01); C12Q 1/70 (2013.01); C12N 2750/14143 (2013.01); C12N 2750/14152 (2013.01); C12N 2830/002 (2013.01)] 17 Claims
OG exemplary drawing
 
1. A circular nucleic acid comprising in 5′ to 3′ direction
(i) at least one adeno-associated virus (AAV) inverted terminal repeat (ITR) sequence;
(ii) at least one AAV promoter which is capable of being activated by at least one helper polypeptide or helper polynucleotide originating or derived from a virus selected from Adenoviridae and Herpesviridae;
(iii) at least one AAV rep gene coding sequence under the control of said promoter of (ii);
(iv) an AAV promoter which is capable of being activated by said at least one helper polypeptide or helper polynucleotide originating from a virus selected from Adenoviridae and Herpesviridae;
(v) a transgenic coding sequence under the control of said promoter of (iv); and
(vi) an adeno-associated virus (AAV) inverted terminal repeat (ITR) sequence;
wherein said circular nucleic acid does not comprise an AAV cap gene.